As previously reported, Craig-Hallum initiated coverage of Clover Health (CLOV) with a Buy rating and $6 price target The firm believes Clover Health is a disrupter in the physician enablement and Medicare Advantage markets and its Clover Assistant, which utilizes AI and ML, is changing the way patients are treated, and in turn is reducing cost of care and ultimately leading to greater cash flow and earnings to shareholders.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLOV: